NF2 and teratoma: Then, the WT and NF2−/− 1 hiPSCs were injected into severe combined immunodeficiency mice for an in vivo teratoma formation assay (Figure 1F; Figure S1K, Supporting Information).[12] On average, mice receiving WT hiPSCs developed significantly larger renal teratomas than those receiving NF2−/− 1 hiPSCs (n = 3, mean± standard deviation [SD] area: 1967.7 ± 1276.5 vs 45.5 ± 40.2 mm2; *p < 0.05) (Figure S1L, Supporting Information).